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ABSTRACT
Objective: Liv52, a nontoxic herbal preparation is reported to be clinically active in hepatotoxicity and a wide range of hepatic disorders. This studywas undertaken to evaluate the mutagenic/antimutagenic potential of Liv52 using Salmonella mutagenicity test.
Methods: Ames Salmonella/Mammalian - microsome mutagenicity test was used to evaluate the mutagenic or antimutagenic potential of Liv52.
Salmonella typhimurium tester strains TA1537, TA1538, TA100, and TA102 were used for mutagenicity testing. The antimutagenicity study wascarried out in tester strains TA1538 and TA100 against various standard mutagens with and without metabolic activation.
Results: Liv52 did not show any mutagenic potential both with and without metabolic activation, whereas in TA1538 and TA 100 tester strains, Liv52showed 48.4% and 47.2% of inhibition of his+ revertants induced by 4-nitro-O-phenylenediamine, respectively. Further with metabolic activationin TA1538, Liv52 showed 99.8%, 99.8%, and 100% inhibition of his+ revertants induced by 2-aminofluorene, 2-anthranine, and cigarette smokecondensate, respectively. In TA100 maximum of 100%, 100%, 97.7%, and 100% inhibition of his+ revertants induced by 2-aminofluorene, 2-anthranine,benzo(a)pyrene, and cigarette smoke condensate, respectively, were observed. A significant enhancement of inhibition of his+ revertants induced byall the above said mutagens were observed in preincubation modification method.
Conclusion: Liv52 was found to be nonmutagenic in Salmonella assay, whereas manifested the antimutagenic potential both with and withoutmetabolic activation. The enhanced antimutagenic activity of Liv52 on preincubation indicates that the antimutagenic factor(s) may be desmutagenicin nature. The exact mechanism by which Liv52 exerts antimutagenic potential is not known. The possibility of having diverse antimutagenic factorsin Liv52 which act by different mechanisms are strongly indicated.
Keywords: Liv52 syrup, Salmonella mutagenicity test, Ames test, Desmutagens.© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i3.16148
INTRODUCTIONThe   phytochemicals   are   secondary metabolic products producedby plants in response to environmental stresses. Thousands of thesephytochemicals have been identified and when consumed in humandiet, may affect chronic disease risk. Of well over 2000 preparationsknown to the modern practitioner of Ayurveda, nearly 1500 are ofplant origin [1]. Susruta Samhita refers to 700 drugs including a smallnumber, which were not available in the country in that time. India hasbeen exposed for well over a century to the application of allopathicmedicines with their definite merits as well as failings.The studies carried out on antimutagenic effects of the ayurvedictherapies were critically reviewed, their protocol studied, and thesignificant results have been pointed out as this effect may accountfor their therapeutic effect to great extent [2]. The ayurvedic herbshave antimutagenic and antiviral activity occupy an importantplace in the ayurvedic system of medicine and are used in thetreatment of various ailments either alone or from a part of variousformulations [3].The mutagenicity refers to the induction of permanent transmissiblechanges   in   the   structure   of   genetic   material   within   cells   andorganisms [4,5]. The mutations are caused by mutagens such asreactive oxygen species (ROS), ultraviolet radiation, ionizing radiation,pollution, and are also the end products of normal metabolic processesof aerobic organisms [6-8]. Oxidative stress caused by ROS is knownto cause tissue injury and can include damage to DNA, proteins, and
lipids [9,10]. Oxidative injury to DNA occurs when oxygen radicals reactwith DNA [6]. If not repaired, the changes in nucleic acid bases and thebreaks in the DNA chain that occur after free radical reactions lead toDNA mutation and mutagenic forms of DNA [4,10].The term genotoxicity is a broader concept than mutagenicity anddescribes the capacity of the compounds to affect the DNA structure orthe cellular apparatus and topoisomerases, which are responsible forthe genome fidelity. Genotoxic effects on DNA are not always relatedto mutations [11,12]. The mutations are created mainly by externalfactors, including chemical and physical agents, called mutagens. Inaddition,  the  mutations  can  occur  spontaneously  due to  errors  inDNA replication, repair,  and recombination.  In  general,  mutationscan be grouped into negative, neutral, positive, lethal, and sublethal.The  mutagenic  changes  that  occur  in  germline  cells  can  be  passedto future generations, whereas somatic mutations may contributeto  the  pathogenesis  of various  pathological conditions,  includingcancer [13-16].Antimutagenic agents are able to counteract the effects of mutagens.Therefore, knowledge on the mode of action of certain mutageniccompounds provides a basis for an explanation of how antimutageniccompounds work. Identifying the antimutagenic compounds are amongthe most promising areas of research in recent years [17]. In this study,the mutagenic and antimutagenic potential of Liv52 was evaluated byemploying Salmonella mutagenicity test with and without metabolicactivation.
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Liv52 syrupLiv52 syrup is a patented product of Himalaya drugs and Co. Indiacomprising  a  standardized  mixture  of  the  plants Capparis  spinosa(13.6 mg/ml), Cichorium intybus (13.6 mg/ml), Solanum nigrum(6.4   mg/ml), Terminalia   arjuna (6.4   mg/ml), Cassia   occidentalis(3.2 mg/ml), Achillea millefolium (3.2 mg/ml),  and Tamarix gallica(3.2 mg/ml).
ChemicalsNutrient broth and agar were purchased from HiMedia LaboratoriesPvt. Ltd. 2-aminofluorene(2-AF), 2-anthranine (2-AN), benzo(a)pyrene(B(a)P), 4-nitro-O-phenylenediamine (NPD), butylated hydroxyanisole(BHA), D L α tocopherol (Vitamin E), β naphthoflavone, phenobarbitonesodium, cumene hydroperoxide, 2-aminoacridine, dantron, D-biotin,and L-histidine were purchased from Sigma Chemical Company; NADPand glucose 6 phosphate were from Sisco Research Laboratories, India,and Dextrose, KCl, MgCl , and other buffer components were from SDFine Chemicals, India.
Salmonella tester strains and mutagenicity test
Salmonella typhimurium tester strains TA1537, TA1538, TA100, andTA102 were kindly supplied from Bruce N Ames Laboratory, Universityof California, USA. An optimum association of standard tester strainsfor maximum detection of mutagens was used in this study [18]. Theplate incorporation and preincubation modification method usingtester strains with and without metabolic activation were carried outessentially [19].
Metabolic activationRat liver S9 fraction was used where induction of liver enzymes wasdone using phenobarbitone and beta-naphthoflavone [20,21]. S9mixture was prepared freshly before the test by adding cofactors (8 mmMgCl , 33 mm KCl, 5 mm glucose 6 phosphate, and 4 mm NADP at thepH 7.4) to 50 µl of S9 [19].
MethodsAmes Salmonella/mammalian - microsome mutagenicity test (an in vitroshort-term mutagenicity test) was used in this study. S. typhimuriumtester strains TA1537, TA1538, TA100, and TA102 were used formutagenicity testing. The antimutagenicity study was conducted usingtester strains TA1538 and TA100 against various standard mutagenswith and without metabolic activation.
Mutagenicity assayAll the tester strains of S. typhimurium were analyzed for mutagenicityassay with and without S9 mix. The molten soft agar of 2 ml, variousconcentrations of the test compound (10 to 500 µl) of Liv52, 0.1 mlof overnight bacterial culture, and 0.5 ml of S9 mix (wherever used)were added, gently mixed and poured over minimal glucose agarmedium and incubated at 37°C for 48 hrs. After incubation, the plateswere counted  for his+ revertants. The  experiment was performedin duplicate using the similar procedure for all the concentrations.The results were determined as mean of six plates per point withstandard deviation and viable cell count as approximately 1–2 ×109 cfu/ml. The positive mutagenic controls including 4-Nitro-O-phenylenediamine (-S9) for TA1538 and TA100; aminoacridine (-S9)for TA1537; cumene hydroperoxide (-S9) for TA102, 2-aminofluorne,2-antramine, and Benzo(a)pyrene (+S9) for TA1538 and TA100,Emodin (+S9) for TA1537, and dantron (+S9) for TA102 were used.All the solutions were prepared freshly by dissolving in dimethylsulfoxide.
Antimutagenicity assayFor antimutagenicity assay, plate incorporation method andpreincubation method were used by incorporating the tester strainsTA1538 and TA100. For plate incorporation assay to 2 ml of the molten
soft agar various concentrations of test compound (10 to 500 µl),0.1 ml of overnight bacterial culture, 0.1 ml of known appropriatepositive mutagen control, and 0.5 ml of S9 mix (wherever used) wereadded aseptically and poured over minimal glucose agar medium andincubated at 37°C for 48 hrs. For antimutagen control, BHA and Dltocopherol were used.For preincubation method, 0.1 ml of overnight culture, variousconcentrations of test compounds, optimal concentration of appropriateknown mutagen control, and 0.5 ml of S9 mix were added in steriletubes, mixed thoroughly using vortex mixture and incubated at 37°C for20-30 minutes. This mixture was added to molten top agar and pouredon the surface of minimal glucose agar and continued further as in plateincorporation method. The results were expressed as the mean of sixplates from two independent experiments with standard deviation.Antimutagenicity or percentage of inhibition of mutagenicity by Liv52was calculated using formula as given below.Antimutagenicity/percentage of inhibition of mutagenicity = (a−b)/(a−c)×100Where,a = number of his+ revertants induced by positive mutagen,b = number of his+ revertants induced by the positive mutagen in thepresence of test Compound,c = number of his+ revertants induced by the test compound alone.
Statistical evaluationStatistical analysis was performed using Karl Pearson CorrelationCoefficient method. Statistical Package for the Social Sciences (SPSS)ver.15.0 was used.
RESULTS AND DISCUSSIONThe present investigation depicts the antimutagenic potential ofvarious concentrations of Liv52 in S. typhimurium reverse mutationassay. The test preparation was found to be nontoxic to the testerstrains at different doses with or without metabolic activation. Thecharacteristics his+ revertants patterns of the standard tester strains tovarious standard mutagens were shown in Table 1. The viable countwas approximately 1-2 × 109 cells/ml in all the tester strains (TA1537,TA1538, TA100, and TA102).Liv52 failed to  induce  his+ revertants  in  all  the four tester  strainseither in the presence or absence of metabolic activation by plateincorporation method thereby found to be nonmutagenic in Ames test(Table 2).The effect of Liv52 on NPD induced mutation frequency by plateincorporation method was depicted in Table 3. It was very clearlydefined and proved that Liv52 inhibited NPD induced his+ revertantssignificantly in both the strains that were dose-dependent. In TA1538,the highest inhibitory effect was 48.4% and in TA100 it was 47.2% atthe dose of 100 µl of Liv52 per plate.Fig. 1 Highlighted the effects of Liv52 on NPD induced mutationfrequency in TA1538 and TA100 by preincubation method. Further,there was a significant enhanced inhibitory effect on preincubation(63.1% in TA1538 and 61.8% in TA100).The effect of Liv52 on 2-aminofluorene, 2-anthramine, and cigarettesmoke condensate-induced mutation frequency in TA1538 by plateincorporation method was well defined in this study (Table 4). Fromthese data, it was obvious that in TA1538, Liv52 reduced his+ revertantsinduced by the above said indirect mutagens, in a dose-dependentmanner. At a dose of 100 µl of Liv52 per plate, the percentage inhibitionsof his+ revertants were the highest of 99.8 for 2-AF, 99.8 for 2-AN, and100 for CSC. Further, an increase of the test compound in the bioassaydid not make a significant difference in the inhibitory effect (Correlationcoefficient were > 0.5 and p<0.005).
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The effect of Liv52 on 2-aminofluorene, 2-anthramine, benzo(a)pyrene,and cigarette smoke condensate-induced mutation frequency in TA100by plate incorporation method was well defined in this study. From thesedata, it was obvious that in TA100 also Liv52 reduced his+ revertantsinduced by the above said indirect mutagens, in a dose-dependentmanner (Correlation coefficient were >0.5 and p<0.005). For the doseof test compound, 100 µl per plate the percentage inhibitions of his+revertants were the highest of 100 for 2-AF, 100 for 2-AN, 97.7 for B[a]P, and 100 for CSC (Table 5).Figs. 2 and 3 depict the effect of Liv52 on the above said indirectmutagens induced mutation frequency in TA1538 and TA100,respectively, by preincubation method. It was clear from the figures thatthere was a significant enhancement in inhibitory action by Liv52 onpreincubation (Correlation coefficient was > 0.5 and p<0.005).
DISCUSSIONLiv52, a polyherbal ayurvedic preparation was found to benonmutagenic  in  Ames test.  The  antimutagenic  potential  of  Liv52was demonstrated against NPD induced mutagenesis in the absenceof metabolic activation in both the tester strains TA1538 and TA100.Liv52 exhibited antimutagenicity against 2-AF, 2-AN, and CSC inducedmutagenesis in TA1538 and also against 2-AF, 2-AN, B(a)P, and CSCin TA100 in the presence of metabolic activation. It was evident fromthe  data  that  the  antimutagenic  activity  of  Liv52 was  more  potentin  the  presence  of  metabolic  activation  than  in  the  absence  of  S9mix (Correlation coefficient was >0.5 and p<0.005). Further, it wasnoticed that the antimutagenic activity of Liv52 against both directand S9 dependent mutagens was comparatively more in TA100 thanin TA1538. These results indicate that Liv52 inhibits his+ revertants
Table 1: Characteristic reversion patterns of standard tester strains to diagnostic mutagens
Diagnostic mutagens His+revertants/plate
TA1537 TA1538 TA100 TA102
−S9 +S9 −S9 +S9 −S9 +S9 −S9 +S9Spontaneous revertants 8±1 15±2 15±1 23±2 143±11 161±9 386±29 409±33Aminoacridine 858±51 - - - - - - -Cumene hydroperoxide - - - - - - 1060±93 -4-nitro-o- phenylene diamine - - 671±41 - 539±31 - - -Sodium azide - - - - 725±56 - - -2-Anthramine - 331±16 - 608±42 - 721±50 - -2-amino fluorine - - - 633±39 - 526±38 - -Benzo (a) pyrene - - - - - 621±40 - -7,12-dimethyl benzanthracene - - - - - 783±56 - -Dantron - - - - - - - 1108±83Cigarette smoke condensate - - - 201±9 - 433±26 - -Results were expressed as the mean of six plates from the two independent experiments with standard deviation. Viable cell count was approximately1-2 × 109 cells/ml.
Table 2: Nonmutagenicity of Liv52 syrup in tester strains TA1537, TA1538, TA100 and TA102 with and without S9 mix by plate
incorporation method
Various concentrations His+revertants/plate
of Liv52 syrup TA1537 TA1538 TA100 TA102
−S9 +S9 −S9 +S9 −S9 +S9 −S9 +S9Spontaneous revertants 9±1 15±2 13±2 21±2 141±10 158±12 378±29 412±3610 µl/plate of Liv52 syrup 9±1 13±1 13±1 23±2 129±10 159±13 371±29 408±2925 µl 12±1 10±2 16±1 21±1 139±12 170±11 385±35 412±3150 µl 13±2 12±1 21±2 29±2 153±11 149±10 391±31 422±2975 µl 10±1 18±2 12±1 23±1 133±9 158±12 402±39 410±51100 µl 9±1 15±2 12±1 19±1 155±16 168±1 394±29 429±21200 µl 8±1 14±1 23±2 24±1 166±12 148±9 408±34 437±20500 µl 10±1 10±1 15±1 26±2 143±11 150±12 378±18 426±16Results were expressed as the mean of 6 plates from two independent experiments with standard deviation. Viable cell count was approximately 1-2X 109 cells/ml.
Table 3: Antimutagenicity of Liv52 against NPD induced mutagenesis in TA1538 and TA100 without S9 mix by plate incorporation method
Various concentrations of Liv52 syrup TA1538 NPD (5 µg/plate) % inhibition TA100 NPD (20 µg/plate) % inhibitionSpontaneous revertants 14±2 - 138±12 -689±52 541±5110 µl/plate of Liv52 syrup 589±99 14.3 491±43 12.425 µl 450±36 35.4 426±32 28.550 µl 364±31 48.1 375±29 41.275 µl 321±29 54.4 352±26 46.9100 µl 263±18 63.1 292±21 61.8200 µl 271±19 61.9 298±20 60.3500 µl 268±23 62.4 294±23 61.3Results were expressed as the mean of 6 plates from two independent experiments with standard deviation. Viable cell count was approximately 1-2X 109 cells/ml. (Correlation coefficient were > 0.5 and p value were < 0.005).
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Table 4: Antimutagenicity of Liv52 syrup against 2-AF, 2-AN, CSC induced mutagenesis in TA1538 with S9 mix by plate incorporation method
Various concentrations His+revertants/plate
of Liv52 syrup 2-AF (5 µg/plate) % inhibition 2-AN (1 µg/plate) % inhibition CSC (100 µg/plate) % inhibitionSpontaneous revertants 23±2 - 25±2 - 22±1 -612±51 636±43 206±1710 µl/plate of Liv52 syrup 311±23 51.1 321±26 51.6 127±9 42.925 µl 162±11 76.4 191±16 72.8 74±8 71.750 µl 27±3 99.3 52±6 95.6 39±4 90.875 µl 22±2 100.2 28±2 99.5 24±3 98.9100 µl 23±1 100 24±2 100.2 20±3 101Vitamin E (10 µl/plate) 110±9 85.2 103±9 87.2 51±6 84.2BHA (100 µg/plate) 201±18 69.8 206±18 70.4 86±9 65.2Results were expressed as the mean of 6 plates from two independent experiments with standard deviation. Viable cell count was approximately 1-2 X 109 cells/ml.(Correlation coefficient were > 0.5 and p value were < 0.005)
Table 5: Antimutagenicity of Liv52 syrup against 2-AF, 2-AN, CSC, and B (a) P induced mutagenesis in TA100 with S9 mix by plate
incorporation method
Various concentrations His+revertants/plate













inhibitionSpontaneous revertants 161±13 - 159±14 - 163±16 165±12 -525±13 803±72 539±51 432±31`10 µl/plate of Liv52 syrup 299±16 62.1 362±29 68.5 327±36 56.4 295±20 51.325 µl 192±21 91.5 209±22 92.2 214±18 86.4 226±29 77.250 µl 170±13 97.5 160±20 99.8 169±12 98.4 175±19 96.375 µl 160±11 100.3 158±11 100.2 161±14 100.5 160±23 101.9100 µl 158±16 100.8 153±18 100.9 163±18 100 162±20 100.1Vitamin E (20 µl/plate) 161±14 100 173±21 97.8 165±11 99.5 176±12 95.9BHA (100 µg/plate) 263±23 72 292±26 79.3 236±28 80.6 232±28 74.9Results were expressed as the mean of 6 plates from two independent experiments with standard deviation. Viable cell count was approximately 1-2 X 109 cells/mlBHA: Butylated hydroxyanisole
arising by base pair substitution more effectively as compared to theframe shift mechanisms.The exact mechanism, by which Liv52 exerts antimutagenic activity,is not clearly understood. It is a polyherbal formulation with severalingredients. This consistently enhanced activity of antimutagenicityagainst all the above said mutagens in preincubation studies suggeststhat the antimutagenic factors may be desmutagenic in nature [2,22].Moreover, Liv52 exhibited antimutagenic activity against various directand indirect mutagens, and these mutagens bring mutagenesis bydifferent mechanisms, the possibility of having diverse antimutagenicfactors which act by different mechanisms on Liv52 is strongly indicated.Thus, due to the proven antioxidant activity of Liv52, it is an important toassess whether the consumption of aqueous extracts of these constituentscan assist in the prevention or repair of cellular changes caused by theexposure to potentially mutagenic agents, in addition, to the provenbeneficial effects for health and well-being. The protective effect ofaqueous extracts of any medicinal products was determined by testingtheir antimutagenicity potential. Our results are supported by the fact thatthis product showed no mutagenic activity in the previous studies [2,23].The most carcinogens are inactive when present in the environment,on  entering  the system,  they  are  converted  into  active  metabolitesby the carcinogen-metabolizing enzymes, further the protocol haveimprovised a method for detecting chemicals which are potential humancarcinogens or mutagens by adding homogenates of rat liver directly tothe Petri plates thus incorporating an important aspect of mammalianmetabolism into the in vitro test [2,24]. In this study, antimutagenicityof Liv52 was studied by adding homogenates of rat liver to the Petriplates along with the extracts to understand the important aspects ofmammalian metabolism in the in vitro testing.This, ayurvedic product may have better antioxidant activity endowwith the ability to intercept the free radicals generated by cellular
Fig. 1: Antimutagenicity of Liv52 against NPD induced
mutagenesis in TA1538 and TA100 without S9 mix by
preincubation method. Results were expressed as the mean
of 6 plates from two independent experiments with standard
deviation Viable cell count was approximately 1-2 X 109 cells/ml.
metabolism or exogenous sources, such as those resulting from theaction of cyclophosphamide, thereby preventing their damage to lipids,amino acids, proteins, polyunsaturated fatty acid double bonds, andDNA bases [25]. The aqueous extracts of PM and BF can act directly oncompounds that induce mutations in DNA, chemically or enzymaticallyinactivating them, may inhibit the metabolic activation of promutagenicagents, or may scavenge reactive molecules, as explained [23]. Thus, theconsiderable presence of antimutagen in Liv52 certainly contributed totheir effective antimutagenic activity.By this investigation, we clearly observed that the Liv52, which isroutinely used in ayurvedic practice, have considerable antimutagenicactivity, show no cytotoxic activity and may contribute to reducing the
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Fig. 2: Antimutagenicity of Liv52 against 2-AF, 2-AN and CSC
induced mutagenesis in TA1538 with S9 mix by preincubation
method. Results were expressed as the mean of 6 plates from two
independent experiments with standard deviation. Viable cell
count was approximately 1-2 X 109 cells/ml
Fig. 3: Antimutagenicity of Liv52 against 2-AF, 2-AN, B(a)P and
CSC induced mutagenesis in TA100 with S9 mix by preincubation
method. Results were expressed as the mean of 6 plates from two
independent experiments with standard deviation. Viable cell
count was approximately 1-2 X 109 cells/ml
chromosomal damage. Further, Liv52 having antimutagenic potentialin it may play an important role in neutralization of various dietarymutagens and may act as a prophylactic agent against human ill-healthattributable to mutation. Thus, the consumption of this ayurvedicproduct can bring added benefits and protection to individuals and alsoimproving their quality of life and health. Further study in these aspectsusing some other in vitro and in vivo will test be warranted beforefinalizing the product as more successful.
CONCLUSIONLiv52 was found to be nonmutagenic in Salmonella assay, whereasmanifested the antimutagenic potential both with and withoutmetabolic  activation.  The  enhanced  antimutagenic  activity of  Liv52on preincubation indicates that the antimutagenic factor(s) may bedesmutagenic in nature. The exact mechanism by which Liv52 exertsantimutagenic potential is not known. The possibility of having diverseantimutagenic factors in Liv52 which act by different mechanisms arestrongly indicated.
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